Navigating Your Toughest Price And Market Access Challenges

NAVLIN by EVERSANA is a single, integrated platform that combines data, software and insights to answer your most challenging price and access questions.

We help you plan and evaluate strategies to achieve success in U.S. and global markets.

Explore NAVLIN

Comprehensive. Intuitive. Integrated.

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Data

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Price & Access Software

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Insights

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Daily

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

NAVLIN Revenue Management

What’s New

NAVLIN’s new release makes it easier to navigate the most complex pricing decisions. It provides enhancements across the full lifecycle and is optimized for early access and launch support.

The new AI assistant is now available across the platform and features natural language, AI-driven querying of the pricing database. Those who are software users will see enhancements to predictability models.

What’s New

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Software

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Insights

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Daily

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Revenue Management

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

What’s New

What’s New

NAVLIN’s new release makes it easier to navigate the most complex pricing decisions. It provides enhancements across the full lifecycle and is optimized for early access and launch support.

The new AI assistant is now available across the platform and features natural language, AI-driven querying of the pricing database. Those who are software users will see enhancements to predictability models.

Experience the
NAVLIN difference

650+
Global sources monitored daily for price, HTA, policy and tender data
+99%
Accuracy of real-time reimbursement, HTA and tender data
<24
hours Speed of updates made from time of publication
4,000+
Medical and pharmacy decision-making executives included in NAVLIN Insights survey panels
24x7
Continuous operations and support
99.5%
Customer satisfaction with market research insights
Real quotes from real clients

Client Delight

This is an amazing tool. The data quality, insights, and user-friendliness are far superior to any other pricing database I’ve used in my career.

Enric Muñoz

Sr. Director, Global Strategic Pricing Head, Takeda

To say thank you seems so trivial. I really appreciate all the hard work and time that you all have invested.

Sr. Director, Global Strategic Pricing Head, Takeda

My team literally could not do what they do without this solution.

Sr. Director, Market Access

Intelligent, intuitive, insightful, helpful, and responsive!

US Payer & Channel Access, Pfizer

NAVLIN Daily News

Checkout Today’s News

SMC Backs 6 New Meds Including Mounjaro

The Scottish Medicines Consortium (SMC) has today announced its latest advice on six newly licensed medicines, covering a range of therapeutic areas including weight management, blood cancer, sickle cell disease, ulcerative colitis, and myelofibrosisNotable approvals include Eli Lilly’s Mounjaro (tirzepatide) and GSK’s Omjjara (momelotinib) Scotland has become the first country in the UK to back NHS use of the Eli Lilly therapy for weight management. Specifically, SMC recommended the therapy for weight loss and weight maintenance when accompanied by a reduced-calorie diet and increased physical activity

PPIC: Thank You!

Last week, NAVLIN held its third Pharma Pricing Innovation Conference (PPIC) at the Mövenpick in Basel, where more than 100 industry experts came together to network and share their insights Members of the NAVLIN team, industry, and payers shared their expertise with the crowd: The final day saw detailed discussions on setting price corridors using NAVLIN, negotiating drug pricing for combination oncology products, and forecasting loss-of-exclusivity, among other topicsInsight into the impact of the changing market in China and a discussion on pricing in lower to middle income countries (LMICs) provided a diverse range of perspectives. Merck's Anita Gandola wrapped up the final day's sessions with insights on China's NRDL and new launch dynamics

Pharma Pricing Innovation Conference: Day One

Yesterday was the first full day of our Pharma Pricing Innovation Conference (PPIC) at the Mövenpick in BaselMore than 100 attendees joined us to engage in discussions around global market dynamics, pricing excellence and the future of the NAVLIN software, among many other topicsThe speakers covered the pricing and commercial strategy integration, rare disease and oncology pricing, and implementation of various NAVLIN offerings. The day focused on the event's overarching theme of "Innovate, Accelerate, Integrate"

Pricing & Contracting USA: Update on 340B Litigation…

William Sarraille provided an update on litigation regarding the 340B Drug Pricing Program and discussed some potential changes to the program at this year's Pricing & Contracting USA conferenceHe noted that cases focused on the use of contract pharmacies have had very mixed results in the courts—some rulings have concluded that contract pharmacy restrictions imposed by manufacturers are consistent with statute; others have concluded the opposite. Sarraille also explained that action on 340B has now shifted to the states. He noted that several states have passed laws intended to clarify requirements and define terms within the discount program. However, these laws create their own significant legal challengesAccording to Sarraille, manufacturers are looking to elevate these lawsuits to the Supreme Court

Pharma Pricing Innovation Conference: Workshop Day

Yesterday was day zero - workshop day - of NAVLIN's Pharma Pricing Innovation Conference (PPIC) at the Mövenpick in BaselAttendees joined us to engage in pre-conference interactive workshops based on pricing and tender, led by Gerardo Peccia and Paolo Correale, among other NAVLIN experts. The speakers covered optimal tendering approaches, loss-of-exclusivity We're looking forward to welcoming the rest of the attendees today, for another day of interactive discussions about key insights and best practices to manage pricing globally

Pricing & Contracting USA: Market Changes Already…

At this year's Pricing & Contracting USA conference, James Stansel, Executive Vice President, General Counsel and Corporate Secretary, the Pharmaceutical Research and Manufacturers of America (PhRMA), discussed some of the challenges facing manufacturers in the U.S. market and how these factors are already impacting research & development (R&D) decisionsThese challenges include the growing role of PBMs and insurers, the expansion of the 340B program, and government price controls implemented through laws like the Inflation Reduction Act (IRA) and state prescription drug affordability boards (PDABs)Stansel said that these market forces are already impacting innovation and 50-75% of PhRMA's member companies believe that R&D decisions at their organizations will be influenced by changes like the IRA. To counter this impact, he suggests that manufacturers should continue raising awareness of the IRA’s implications, focusing on preventing its expansion, and preparing to fix unintended consequences like the "pill penalty." Stansel noted that the Centers for Medicare & Medicaid Services (CMS) can also help by improving the implementation process and seeking more stakeholder and patient input

EFPIA's Andy Powrie-Smith on the Changing EU Landscape

At Reuters Pharma Europe 2024, Andy Powrie-Smith, Executive Director of Communications & Partnerships at the European Federation of Pharmaceutical Industries and Associations (EFPIA), spoke on a panel discussion around the EU’s pharmaceutical legislation revision. While the general agreement was that the review is a “positive step,” it does still present uncertainties in a number of areas.As the European Union prepares for the review, it can’t be forgotten that the joint Health Technology Assessment (HTA) regulation is simultaneously impending, meaning the industry has to learn to navigate both these changes at once. Speaking to NAVLIN Daily after his panel, Powrie-Smith delved into the core aspects of the upcoming changes, exploring how to balance innovation, competitiveness, and patient access across Europe without penalizing the pharma industry too heavilyAs the legislation moves into the trialogue phase between the European Parliament, several key concerns remain. Powrie-Smith worries that the changes to IP frameworks and data protection could still weaken incentives for R&D in Europe, and that the legislation may not adequately address the core issue of access, availability, and affordability of medicines – problems which he believes are best tackled through cooperation, rather than waiting for legislation to pass

EURIPID: Where Are we Now, and What's to Come?

Speaking at a recent conference, experts discussed the evolution of the EURIPID Collaboration. Speakers noted that despite its time-consuming operation, the database is valuable for analyzing price differences and planning cost reductions. Current limitations discussed include the disparity between list and net prices, and the delay in incorporating prescription volume dataHowever, with EU funding to enhance the platform's functionality and a seat on the National Competent Authorities on Pharmaceutical Pricing and Reimbursement (NCAPR), EURIPID's influence on the European P&R environment is poised to expandIn Norway, the EURIPID database assists in the annual re-evaluation of pharmaceutical prices. It ensures that the pricing remains appropriate despite currency fluctuations. Head of Unit Safe Use at the Norwegian Medicines Agency, Helga Festøy, emphasized the crucial role of EURIPID in controlling pricing and helping patients afford necessary medications

NICE's New Prioritization Board to "Work in…

The National Institute for Health and Care Excellence (NICE) is introducing a new prioritization board to streamline its system for selecting topics. In a recent document, NICE addressed public concerns raised about the board's relation to the Voluntary Scheme for Pricing, Access, and Growth (VPAG), stating that the board will not change the VPAG and primarily, it generally won't include medicines under the 2024 VPAG in its prioritization processThe paper clarifies that the prioritization board will only consider new medicines and line extensions if there is uncertainty about meeting VPAG commitments - these cases will be evaluated using the Stage 2 prioritization framework.Feedback showed that stakeholders welcomed the inclusion of Highly Specialized Technologies (HST) and rare disease treatments being considered by the prioritization board. However, concerns were raised about the evaluation process and the potential for treatments for rare conditions to be disadvantaged. In response, NICE committed to applying a balanced approach, avoiding a fixed scoring system. For ultra-orphan drugs, they will be assessed based on HST criteria, skipping the Stage 2 framework

Germany's Federal Council Rejects Confidential Drug…

The German Federal Council (Bundesrat) has rejected the proposal for confidential drug reimbursement amounts in the Medical Research Act (MFG). The Council essentially argues that the move would undermine transparency in health economics and entail high bureaucratic and financial costs, without bringing tangible benefitsHealth insurers like AOK and GKV-Spitzenverband welcomed the Council's decision, emphasizing that secret drug prices could drive up pharmaceutical costs by billions of euros and increase the burden for premium payers. They further argue that transparency enables doctors to prescribe more economicallyThe rejection from the Bundesrat over the weekend means confidential pricing in Germany is looking far less likely than before, as the G-BA also recently rejected the bill

Connect With Our Team Of Global Experts

Contact Us

Feel free to get in touch with us via email, live chat, or schedule a meeting!